Clinical Trial Update: Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication? [Phase 4]

View source ↗

Summary

A Phase 4 trial is evaluating whether a GLP-1 receptor agonist can prevent deterioration of metabolic state in prediabetic and diabetic patients with schizophre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prediabetes
• Schizophrenia
• Type 2 Diabetes Mellitus

Drugs mentioned

• GLP-1 receptor agonist

Snippet

Sponsor: Anders Fink-Jensen, MD, DMSci | Conditions: Metabolic Disturbance, Schizophrenia | Phase 4 | Status: ACTIVE_NOT_RECRUITING